ArticleHepatology (Baltimore, Md.)2020
Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Postmenopausal Women.
Open access · greenAbstract read
In one paragraph
Article in Hepatology (Baltimore, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
3.3field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Molecular mechanisms of sex hormones in Hepatocellular Carcinoma: a systematic review.Molecular biology reports · 2025Pooled it
- Oral contraceptive use and risk of liver cancer: a population-based study, systematic review, and meta-analysis.The Lancet. Oncology · 2025Pooled it
- Exogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the UK Biobank.British journal of cancer · 2020Pooled it
- Association of testosterone and sex hormone-binding globulin with chronic liver disease outcomes across sex and menopausal status.Biology of sex differences · 2026Article
- G20 Country Burden of High BMI-Related Liver Cancer: Trends from 1990 to 2021 and Projections to 2050.Journal of epidemiology and global health · 2026Article
- Diagnostic value of betatrophin for hepatocellular carcinoma in patients with liver cirrhosis.Clinical and experimental hepatology · 2026Article
- Two-way increased-risk associations between hepatobiliary cancers and other malignancies: a population-based study.Hepatic oncology · 2025Article
- Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2025Review
- Circulating per- and polyfluoroalkyl substances and liver cancer risk: a nested case-control analysis of individual participant data from 12 prospective cohorts.Environmental health perspectives · 2025Article
- Total testosterone, sex hormone-binding globulin, and free testosterone concentrations and risk of primary liver cancer: A prospective analysis of 200,000 men and 180,000 postmenopausal women.International journal of cancer · 2025Article
- Article
- Interplay of Cardiometabolic Syndrome and Biliary Tract Cancer: A Comprehensive Analysis with Gender-Specific Insights.Cancers · 2024Review
- Point-based risk score for the risk stratification and prediction of hepatocellular carcinoma: a population-based random survival forest modeling study.EClinicalMedicine · 2024Article
- An Examination of Liver Cancer Incidence in California.Journal of registry management · 2024Article
- Changing Epidemiology of Hepatocellular Carcinoma Within the United States and Worldwide.Surgical oncology clinics of North America · 2024Review
- Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes.Cancer reports (Hoboken, N.J.) · 2023Review
- Endogenous sex steroid hormones and risk of liver cancer among US men: Results from the Liver Cancer Pooling Project.JHEP reports : innovation in hepatology · 2023Article
- Disparities in stage at diagnosis for liver cancer in China.Journal of the National Cancer Center · 2023Article
- Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries.Hepatobiliary surgery and nutrition · 2023Article
- RETRACTED: Menstrual Factors, Reproductive History and Liver Cancer Risk: Findings from a Prospective Cohort Study in Chinese Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 13 institutions in 4 countries.
Jessica L PetrickDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0001-6580-450X
Andrea A FlorioDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-5114-7083
Xuehong ZhangChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA.
Anne Zeleniuch-JacquotteDepartment of Population Health, New York University School of Medicine, New York, NY.ORCID 0000-0001-9350-1303
Jean Wactawski-WendeDepartment of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY.ORCID 0000-0003-3096-9595
Stephen K Van Den EedenDivision of Research, Kaiser Permanente Northern California, Oakland, CA.ORCID 0000-0002-5599-8387
Frank Z StanczykDepartment of Obstetrics and Gynecology, University of Southern California Keck School of Medicine, Los Angeles, CA.
Tracey G SimonDivision of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-0610-5287
Rashmi SinhaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-2466-7462
Howard D SessoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.ORCID 0000-0002-9698-9954
Catherine SchairerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0001-7671-4972
Lynn RosenbergSlone Epidemiology Center, Boston University, Boston, MA.ORCID 0000-0003-2760-2987
Thomas E RohanDepartment of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY.
Mark P PurdueDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-1177-3108
Julie R PalmerSlone Epidemiology Center, Boston University, Boston, MA.ORCID 0000-0002-6534-335X
Martha S LinetDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-1687-5587
Linda M LiaoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-1923-5294
I-Min LeeDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.ORCID 0000-0002-1083-6907
Jill KoshiolDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-3832-6204
Cari M KitaharaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Victoria A KirshEpidemiology Division, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Jonathan N HofmannDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-1043-5812
Chantal GuillemettePharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec-(CHU de Québec) Research Center-Université Laval, Québec, QC, Canada.ORCID 0000-0002-1113-1212
Barry I GraubardDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-6787-1105
Edward GiovannucciDivision of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
J Michael GazianoDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Susan M GapsterEpidemiology Research Program, American Cancer Society, Atlanta, GA.
Neal D FreedmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-0074-1098
Lawrence S EngelDepartment of Epidemiology, University of North Carolina, Chapel Hill, NC.ORCID 0000-0001-9268-4830
Dawn Q ChongDivision of Medical Oncology, National Cancer Centre Singapore, Singapore.ORCID 0000-0002-8293-4493
Yu ChenDepartment of Population Health, New York University School of Medicine, New York, NY.
Andrew T ChanChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA.
Patrick CaronPharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec-(CHU de Québec) Research Center-Université Laval, Québec, QC, Canada.ORCID 0000-0002-0524-7892
Julie E BuringDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.ORCID 0000-0003-2648-8692
Gary BradwinClinical and Epidemiologic Research Laboratory, Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA.ORCID 0000-0001-7026-8318
Laura E Beane FreemanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-1294-4124
Peter T CampbellEpidemiology Research Program, American Cancer Society, Atlanta, GA.
Katherine A McGlynnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-2329-9933
National Cancer Institute · USBrigham and Women's Hospital · USBoston University · USUniversity of Southern California · USCentre hospitalier universitaire de Québec · CAHarvard University · USKaiser Permanente · USNational Cancer Centre Singapore · SGNational Cancer Institute · UANew York University · USUniversity at Buffalo, State University of New York · USUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CA
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2MWomen's Health Study: Continued Follow-upR01CA047988 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 1991 to 2014
$28.2MRESEARCH IN ENVIRONMENTAL HEALTH SCIENCES (CENTER GRANT)P30ES000260 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZELIKOFF, JUDITH TERRY · 1985 to 2020
$26.1MA Follow-up Study for Causes of Cancer in Black WomenU01CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Kimberly A. Bertrand, Yvette C Cozier · 2017 to 2026
$24.0MLong Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3MFOLLOW-UP STUDY FOR CAUSES OF ILLNESS IN BLACK WOMENR01CA058420 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 1999 to 2013
$20.7MStudies of Rare CancersZIACP010158 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MCGLYNN, KATHERINE · 2009 to 2025
$19.1MCancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0MCancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5MWomen's Health Study: Continued Follow-UpR01HL080467 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E. · 2005 to 2010
$4.5MIntramural NIH HHS ZIA CP010158NCI NIH HHS Intramural FundsNCI NIH HHS K07 CA188126NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA016087NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA047988NCI NIH HHS R01 CA058420NCI NIH HHS U01 CA164974NCI NIH HHS U01 CA167552NCI NIH HHS U01 CA182913NCI NIH HHS U01 CA182934NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA182913NCI NIH HHS UM1 CA182934NCI NIH HHS UM1 CA186107NHLBI NIH HHS HHSN268201600001CNHLBI NIH HHS HHSN268201600002CNHLBI NIH HHS HHSN268201600003CNHLBI NIH HHS HHSN268201600004CNHLBI NIH HHS HHSN268201600018CNHLBI NIH HHS R01 HL043851NHLBI NIH HHS R01 HL080467NHLBI NIH HHS RC1 HL099355NIDDK NIH HHS K24 DK098311NIEHS NIH HHS P30 ES000260
Abstract
BACKGROUND AND
aimsIn almost all countries, incidence rates of liver cancer (LC) are 100%-200% higher in males than in females. However, this difference is predominantly driven by hepatocellular carcinoma (HCC), which accounts for 75% of LC cases. Intrahepatic cholangiocarcinoma (ICC) accounts for 12% of cases and has rates only 30% higher in males. Hormones are hypothesized to underlie observed sex differences. We investigated whether prediagnostic circulating hormone and sex hormone binding globulin (SHBG) levels were associated with LC risk, overall and by histology, by leveraging resources from five prospective cohorts. APPROACH AND
resultsSeven sex steroid hormones and SHBG were quantitated using gas chromatography/tandem mass spectrometry and competitive electrochemiluminescence immunoassay, respectively, from baseline serum/plasma samples of 191 postmenopausal female LC cases (HCC, n = 83; ICC, n = 56) and 426 controls, matched on sex, cohort, age, race/ethnicity, and blood collection date. Odds ratios (ORs) and 95% confidence intervals (CIs) for associations between a one-unit increase in log
conclusionsThis study provides evidence that higher levels of 4-dione may be associated with lower, and SHBG with higher, LC risk in women. However, this study does not support the hypothesis that higher estrogen levels decrease LC risk. Indeed, estradiol may be associated with an increased ICC risk.
Indexed as
AgedCarcinoma, HepatocellularFemaleGonadal Steroid HormonesHumansLiver NeoplasmsMiddle AgedPostmenopauseRisk AssessmentSex FactorsSex Hormone-Binding GlobulinGonadal Steroid HormonesSex Hormone-Binding Globulin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.